A real-world pharmacovigilance study of Certolizumab pegol based on FAERS database

Nature·Aug 5

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

A real-world pharmacovigilance study has been conducted on certolizumab pegol using the FAERS database. The study appears to be part of a broader examination of safety issues related to certain medications, including tumor necrosis factor-alpha inhibitors and other treatments for immune-mediated diseases. The specific focus and findings of the certolizumab pegol study are not clear from the available information.

Full coverage

Conducting a real-world study of Tumor Necrosis factor-alpha inhibitors-induced Systemic Lupus Erythematosus based on the FAERS database

Nature·Feb 26

The Rise of Anti-TNF Biosimilars: Guidelines, Real-World Evidence, and Challenges to Acceptance

EMJ·Nov 4

A real-world safety analysis of infection-related adverse events associated with belimumab, rituximab, and TNF inhibitors using the FAERS database

Nature·Dec 3

Safety of Anti-TNFs in Patients with Immune-Mediated Disease

EMJ·Jul 1

A real-world analysis of FDA Adverse Event Reporting System (FAERS) events for liposomal and conventional doxorubicins

Nature·Mar 1

View original report at Nature ↗